17,261 trials
Seasonal Influenza · Influenza · Influenza Due to Unspecified Influenza Virus
Primary: Cell Mediated Immune (CMI) Responses After In-vitro Restimulation Of Peripheral Blood Mononuclear Cells (PBMC) Following Vaccination. — 631; 655; 1560; 1137 Cells per…
Down Syndrome
Primary: Mean Change From Baseline in V-Scale Composite Score (Sum of 9 Sub-Domains) of Vineland Adaptive Behavior Scales Second Edition-Parent Caregiver Rating Form…
Presbyopia
Primary: Proportion of Subjects With at Least a 3 Line (15 Letter) Improvement in Near Visual Acuity in the Study Eye — 47.22; 47.22; 2.38 percentage of participants — p=0.0009
Diabetic Macular Edema
Primary: Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events — 8; 9; 0; 0 Participants
Hodgkin's Lymphoma
Primary: Objective Response Rate (ORR) — 25.00; 37.50; 75.00; 62.50 percentage of patients
Pruritus
Primary: Peak Itch Intensity Between the Vehicle and Active Treatments During Non-histaminergic Itch Induction — 4.5; 3.94; 5.32; 5.79 Intensity score
Amyloidosis
Primary: Number of Participants With Dose-Limiting Toxicities as Assessed by Reported Data — 0; 1 Participants
Kidney Transplant Failure and Rejection
Primary: Change in Controlled Oral Word Association Test (COWAT) — .44; -2.11; -0.88; -1.78 score on a scale
COVID-19 · SARS-CoV 2
Primary: Number of Participants With Clinical Improvement at Day 14 — 9; 7; 9 Participants
Hepatitis C, Chronic
Primary: HCV Treatment Completion — 22; 22 Participants
Autism · ASD
Primary: Empathic Accuracy Performance
Glioma
Primary: Overall Survival at 12 Months — 74; 92 percentage of participants — p=0.03
Biliary Tract Neoplasms · Cholangiocarcinoma · Bile Duct Cancer
Primary: Progression Free Survival (PFS) — 4.54 Months
Acute Pancreatitis · Intestinal Bacteria Flora Disturbance · Intestinal Dysfunction
Primary: Number of Participants With Gastrointestinal Failure Score Equal 0 — 12; 14 Participants
Metastatic Breast Cancer
Primary: Progression Free Survival. — 5.4; 6.3 months — p=0.71